3M CDI QUICK-CELLS WITH HEPARIN TREATMENT

K980732 · 3M Healthcare · DRY · May 15, 1998 · Cardiovascular

Device Facts

• Record ID: K980732
• Device Name: 3M CDI QUICK-CELLS WITH HEPARIN TREATMENT
• Applicant: 3M Healthcare
• Product Code: DRY · Cardiovascular
• Decision Date: May 15, 1998
• Decision: SESE
• Submission Type: Traditional
• Regulation: 21 CFR 870.4330
• Device Class: Class 2

Intended Use

The CDI 400 Extracorporeal Blod Gas Monitoring System is intended for use during cardiopulmonary bypass procedures when continuous monitoring of blood gases is desired.

Device Story

3M CDI QUIK-CELLS are sterile, single-use components for the CDI 400 Extracorporeal Blood Gas Monitoring System; used during cardiopulmonary bypass. Modification involves application of covalently bound heparin coating to fluid path and use of slightly thicker membrane. Device functions as part of an extracorporeal circuit to facilitate continuous blood gas monitoring. Operated by clinical staff in surgical settings. Heparin coating intended to improve hemocompatibility. Output provides real-time blood gas data to clinicians to assist in patient management during bypass.

Clinical Evidence

No clinical data. Bench testing only.

Technological Characteristics

Sterile, single-use extracorporeal blood gas monitoring cells. Available in 1/4", 1/8", and 1/2" diameters. Features covalently bound heparin coating on fluid path and modified membrane thickness. Designed for integration into CDI 400 monitoring system.

Indications for Use

Indicated for patients undergoing cardiopulmonary bypass procedures requiring continuous blood gas monitoring.

Regulatory Classification

Identification

A cardiopulmonary bypass on-line blood gas monitor is a device used in conjunction with a blood gas sensor to measure the level of gases in the blood.

Predicate Devices

• CDI 400 Extracorporeal Hematocrit/Oxygen Saturation Monitoring System (K890113)
• CDI 100 Extracorporeal Hematocrit/Oxygen Saturation Monitoring System (K902654)

Submission Summary (Full Text)

{0}------------------------------------------------

# 510(k) SUMMARY

This summary of 510(k) safety and effectiveness information is being submitted in Firs summer with the requirements of SMDA 1990 and 21 CFR 807.92. The assigned
510(k) number is

Submitter's Name: Submitter's Address: Contact Person: Phone Number: FAX Number: Summary Date:

3M Health Care 1311 Valencia Avenue, Tustin, CA 92780 Diana Thorson [phone] X233 [phone]

Device Trade Name: CDI 400 Extracorporeal Blood Gas Monitoring System

Device Classification Name:

Cardiopulmonary bypass on-line blood gas monitor and cardiopulmonary bypass in line blood gas sensor (21 CFR 870.4330)

Predicate Devices:

| Product | 510(k) Number | Clearance Date |
|-----------------------------------------------------------------------------|---------------|----------------|
| CDI 400 Extracorporeal<br>Hematocrit/Oxygen Saturation Monitoring<br>System | K890113 | 5/23/89 |
| CDI 100 Extracorporeal<br>Hematocrit/Oxygen Saturation Monitoring<br>System | K902654 | 11/5/90 |

### Device Description:

The 3M CDI H/S QUIK-CELLS with Heparin Treatment are sterile, single-use medical devices. They are available in 1/4", 1/8", and 1/2" diameter sizes. Additionally, the 3M CDI QUIK-CELLS with Heparin Treatment have a covalently bound heparin coating.

## Indications for Use:

The CDI 400 Extracorporeal Blod Gas Monitoring System is intended for use during cardiopulmonary bypass procedures when continuous monitoring of blood gases is desired.

{1}------------------------------------------------

#### Technological Characteristics:

This modification to the 3M CDI QUIK-CELLS includes the application of a covalently bound heparin coating to the fluid path of the device. In addition, the 3M CDI QUIK-CELLS with Heparin Treatment have a slightly thicker membrane. There are no other dimensional changes to the cells due to the addition of the Heparin Treatment.

#### Nonclinical Performance:

The performance characteristics of the 3M CDI OUIK-CELLS with Heparin Treatment were exhaustively tested and compared with the performance characteristics of the currently marketed 3M CDI OUIK-CELLS. All new and existing performance characteristics of the 3M CDI Heparin Coated QUIK-CELLS have been validated.

#### Clinical Performance:

Clinical testing was not performed on these devices.

#### Conclusions from Nonclinical Tests:

The 3M CDI OUIK-CELLS with Heparin Treatment perform as intended according to their performance specifications. The 3M CDI QUIK-CELLS with Heparin Treatment are substantially equivalent to their predicate devices.

Page 2-3

{2}------------------------------------------------

#### 2.2 Safety Literature Search

Although a safety literature search is not required for class II devices, one has been included below.

I certify that I have conducted a reasonable search of all information known or otherwise available to me about the types and causes of safety and/or effectiveness problems that have been reported with cardiopulmonary bypass on-line blood gas monitors and cardiopulmonary bypass in line blood gas sensors within the past five years. I further certify that I am aware of the types of problems to which cardiopulmonary bypass on-line blood gas monitors and cardiopulmonary bypass in line blood gas sensors are susceptible and that the following list of safety and/or effectiveness problems about these devices is complete and accurate:

- 1.) Occlusion of the cell
- Leakage of fluid from the cell, or ingress of air emboli into the 2.) cell
- Loss of sterility 3.)

Below is a bibliography of the materials upon which the above summary is based:

- 1.) Customer Complaint File, various dates, 3M Health Care, CDI Products.
- U.S. Food and Drug Administration Recall Number Z 1084/1085-1. 2.) Initiated by CDI, 3M Health Care on May 20, 1991.
- U.S. Food and Drug Administration Recall Number Z 2628-2 through 3.) Z2633-2. Initiated by CDI, 3M Health Care On December 18, 1991.
- U.S. Food and Drug Administration Recall Numbers Z-635-2 through 4.) Z-645-2. Initiated by CDI, 3M Health Care on February 2, 1992.
- Medical Device Report M174488, filed 1/30/92 by CDI, 3M Health 5.) Care.
- Medical Device Report M174493, filed 2/4/92 by CDI, 3M Health 6.) Care.
- Medical Device Report M268836, filed 2/17/92 by CDI, 3M Health 7.) Care.
- Medical Device Report M268956, filed 2/19/92 by CDI, 3M Health 8.) Care.
- 9.) Medical Device Report M268957, filed 2/19/92 by CDI, 3M Health Care.
- 10.) Medical Device Report M255427, filed 2/13/92 by CDI, 3M Health Care.
- Medical Device Report M255429, filed 2/13/92 by CDI, 3M Health 11.) Care.

{3}------------------------------------------------

- Medical Device Report M174556, filed 2/12/92 by CDI, 3M Health 12.) Care.
- Medical Device Report M174629, filed 2/2/92 by CDI, 3M Health 13.) Care.
- Medical Device Report M174966, filed 4/16/92 by CDI, 3M Health 14.) Care.
- Medical Device Report M174942, filed 4/16/92 by CDI, 3M Health 15.) Care.
- 16.) Medical Device Report M174941, filed 4/16/92 by CDI, 3M Health Care.
- 17.) Medical Device Report M174943, filed 4/16/92 by CDI, 3M Health Care.
- Medical Device Report M174964, filed 4/16/92 by CDI, 3M Health 18.) Care.
- 19.) Medical Device Report M320347, filed 3/14/93 by CDI, 3M Health Care.
- Medical Device Report M377386, filed 3/26/93 by CDI, 3M Health 20.) Care.
- Medical Device Report M377387, filed 3/26/93 by CDI, 3M Health 21.) Care.
- 22.) Medical Device Report M377388, filed 3/26/93 by CDI, 3M Health Care.
- 23.) Medical Device Report M544290, filed 8/5/94 by CDI, 3M Health Care.
- 24.) Medical Device Report M800711, filed 4/17/95 by 3M Health Care.
- Medical Device Report M820946, filed 7/31/95 by 3M Health Care. 25.)
- 26.) Medical Device Report 2023117-1997-00001, filed 3/14/97 bv 3M Health Care.

Printed name of person required to submit 510(k): Diana M. Thorson Signature of person required to submit 510(k): Machines M) theresto Title of person submitting 510(k): Advanced Regulatory Affairs Coordinator Name of Company: 3M Health Care Date: 2/24/98

{4}------------------------------------------------

Image /page/4/Picture/2 description: The image shows the seal of the Department of Health & Human Services (HHS) of the United States of America. The seal features a stylized eagle with three tail feathers, representing the three levels of government: federal, state, and local. The eagle is encircled by the words "DEPARTMENT OF HEALTH & HUMAN SERVICES • USA" in a circular arrangement.

## MAY 1 5 1998

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

Ms. Diana M. Thorson Advanced Requlatory Affairs Coordinator 3M Health Care, Cardiovascular Systems CDI Products 1311 Valencia Avenue Tustin, CA 92780

Re : K980732 3M CDI Quick-Cell with Heparin Treatment Regulatory Class: II (Two) Product Code: DRY Dated: February 24, 1998 Received: February 25, 1998

Dear Ms. Thorson:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Requlations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set-forth in the Quality System Regulation (QS) for Medical Devices: General requlation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or requlations.

{5}------------------------------------------------

#### Page 2 - Ms. Diane Thorson

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at [phone]. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at [phone]. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number [phone] or [phone], or at its internet address "http://www.fda.gov/cdrh/dsma/dsmamain.html".

Sincerely yours,

Thomas J. Callahan

Thomas J. Callahan, Director Division of Cardiovascular, Respiratory, and Neurological Devices Office of Device Evaluation Center for Devices and Radiological Health

{6}------------------------------------------------

Page 1 of 1

510(k) Number (if known): K980732-

3M CDI QUIK-CELLS With Heparin Treatment Device Name:__________________________________________________________________________________________________________________________________________________________________

These cells are to be used with the CDI System Indications For Use: Indications for 6000 Gas Monitoring System, which is intended for 400 Extractporcal brood our heartering by sound.
use during cardiopulmonary bypass procedures when continous monitoring of blood gases is desired.

#### (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Sette a. Cooper le

(Division Sign-Off) Division of Cardiovascular, Respiratory, and Neurological Devices K-98073. 510(k) Number_

Prescription Use X (Per 21 CFR 801.109) OR

Over-The-Counter Use__________________________________________________________________________________________________________________________________________________________

(Optional Format 1-2-96)